| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. A Webb, D Cunningham, JH Scarffe, P Harper, A Norman, JK Joffe, ... Journal of Clinical Oncology 15 (1), 261-267, 1997 | 1184 | 1997 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 409 | 2017 |
| Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO. 17 SY Brulé, DJ Jonker, CS Karapetis, CJ O’Callaghan, MJ Moore, R Wong, ... European journal of cancer 51 (11), 1405-1414, 2015 | 406 | 2015 |
| A review of PARP inhibitors: from bench to bedside C Underhill, M Toulmonde, H Bonnefoi Annals of Oncology 22 (2), 268-279, 2011 | 316 | 2011 |
| Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma O Kondrashova, M Topp, K Nesic, E Lieschke, GY Ho, MI Harrell, ... Nature communications 9 (1), 3970, 2018 | 265 | 2018 |
| Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review PN Butow, F Phillips, J Schweder, K White, C Underhill, D Goldstein, ... Supportive Care in Cancer 20, 1-22, 2012 | 264 | 2012 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 245 | 2018 |
| Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ... JAMA oncology 6 (9), 1405-1409, 2020 | 215 | 2020 |
| Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy TP Hughes, S Branford, DL White, J Reynolds, R Koelmeyer, JF Seymour, ... Blood, The Journal of the American Society of Hematology 112 (10), 3965-3973, 2008 | 199 | 2008 |
| Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor–positive metastatic breast cancer: a randomized phase II study CK Osborne, P Neven, LY Dirix, JR Mackey, J Robert, C Underhill, ... Clinical Cancer Research 17 (5), 1147-1159, 2011 | 198 | 2011 |
| Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised … D Kotasek, G Steger, W Faught, C Underhill, E Poulsen, AB Colowick, ... European Journal of Cancer 39 (14), 2026-2034, 2003 | 197 | 2003 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 163 | 2016 |
| Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers O Klein, D Kee, B Markman, M Michael, C Underhill, MS Carlino, L Jackett, ... Clinical Cancer Research 26 (17), 4454-4459, 2020 | 154 | 2020 |
| Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study J Tie, Y Wang, J Cohen, L Li, W Hong, M Christie, HL Wong, S Kosmider, ... PLoS medicine 18 (5), e1003620, 2021 | 151 | 2021 |
| Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma MK Gandhi, E Lambley, J Burrows, U Dua, S Elliott, PJ Shaw, HM Prince, ... Clinical Cancer Research 12 (2), 460-464, 2006 | 148 | 2006 |
| Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age L Mileshkin, JJ Biagi, P Mitchell, C Underhill, A Grigg, R Bell, ... Blood 102 (1), 69-77, 2003 | 147 | 2003 |
| Prognostic gene expression signature for high-grade serous ovarian cancer J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, ... Annals of Oncology 31 (9), 1240-1250, 2020 | 123 | 2020 |
| Mapping oncology services in regional and rural Australia C Underhill, R Bartel, D Goldstein, H Snodgrass, S Begbie, P Yates, ... Australian Journal of Rural Health 17 (6), 321-329, 2009 | 120 | 2009 |
| Treatment of invasive thymoma with single-agent ifosfamide MS Highley, CR Underhill, FX Parnis, C Karapetis, E Rankin, J Dussek, ... Journal of clinical oncology 17 (9), 2737-2737, 1999 | 118 | 1999 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an … CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ... The Lancet Oncology 24 (4), 323-334, 2023 | 105 | 2023 |
